Skip to main content

NON DIABETIC USE OF INSULIN IN THE MANAGEMENT OF CRHONIC DISEASES AND CANCER. IPT Technique. (Dr.Donato Perez Garcia, MD.1896-1971)


Articles about non diabetic use of insulin
Insulin Potentiation Therapy (IPT/IPTLD) Technique

August 4-6, 1997, Bethesda , Maryland, Medical Hypotheses (20(2):199-210,1986) By: SGA, Donato Pérez García Bellón and Donato Pérez García , Jr.“Insulin Potentiation Therapy: a new concept for management of chronic degenerative disease”.

Radiother Oncol 2006;81(1):112-7
Jordan BF, Beghein N.Crokart N. et al.
“Preclinical safety and efficacy of insulin combined with irradiation”.

Cancer Chemotherapy and Pharmacology
“Insulin induced enhancement of antitumoral response to methotrexate in breast cancer patients”. Lasavio-Prosco E., Cucchi S., Vazquez J., Lasavio- Galante E., Golomar W., Gordon W.

The very first publication of IPT clinical trial data: “IPT very significantly improved clinical outcome of low dose of chemotherapy in patients with advance breast cancer”. December 4, 2003.
“The effect of insulin chemotherapeutic drug sensitivity in human esophageal and lung cancer cells”. Jiao SC, Huang J, Sun Y, Lu SX. Zhonghua Yi Xue Za Zhi.
February 2003.
10;83 (3):195-7 (article in Chinese)
“Insulin significantly enhanced the killing effect of three chemotherapy drugs on esophageal and lung cancer cell’s”.

Medical Hypotheses (2000) 55(4) 330-334, 2000
By: S.G.A, D.P. Garcia Bellon , D.P.Garcia Jr.
“Insulin chemotherapy and the mechanisms of malignancy: the design and the demise of cancer”.
October 1999, pages 94-96
M.D.M Townsend Letter for Doctors and Patients, S.G.A.
“Hoist by one’s own petard: the design and the demise of cancer”.

1981, European Journal of Cancer and Clinical Oncology 17(11):1223-1228.
Alabaster O., Vonderhaar B.K.,Ans Shafie S.M.,
“Metabolic modification by insulin enhances Methotrexate Cytotoxicity in MCF-7 human breast cancer cells”.

Publications and Essays on IPT, also Supportive Studies – Published clinical and in-vitro studies that support the use of  insulin as a biologic response modifier.


1)Poster Presentation at the Third Annual Comprehensive Cancer Management Conference, Washington, DC June 2000

Primary Breast Conserving Treatment for Breast Cancer Using Biologic Response Modification with Insulin in Combination with Non-Toxic Low-Dose Chemotherapy. Steven G. Ayre, M.D.


2)Insulin Shows Promise

Oncology News, 1991, 17(4):1,7


3) Ayre SG, Perez Garcia y Bellon D, Perez Garcia Jr D.  Neoadjuvant low-dose chemotherapy with insulin in breast carcinomas.  Eur J Cancer. 26:1261-2, 1990


4) Ayre SG, Perez Garcia Y Bellon D, Perez Garcia Jr D.  Insulin potentiation therapy:  a new concept in the management of chronic degenerative disease.  Medical Hypotheses 20:199-210, 1986


5) Lippman ME, Dickson RB, Kasid A, et al.  Autocrine and paracrine growth regulation of human breast cancer.  J Steroid Biochem 24:147-154, 1986


6) Hilf R.  The actions of insulin as a hormonal factor in breast cancer.  In:  Pike MC, Siiteri PK, Welsch CW, eds.  Hormones and Breast Cancer, Cold Spring Harbor Laboratory, 1981, 317-337.


7) Cullen JK, Yee D, Sly WS, et al.  Insulin-like growth factor receptor expression and function in human breast cancer.  Cancer Res 50:48-53, 1990


8) Holdaway IM, Freisen HG.  Hormone binding by human mammary carcinoma.  Cancer Res 37:1946-1952, 1977


9) Papa V,  Pezzino V, Constantino A, et al.  Elevated insulin receptor content in human breast cancer.  J Clin Invest 86:1503-1510, 1990


10) Sporn MB, Todaro GJ.  Autocrine secretion and malignant transformation of cells.  N Engl J Med 308:487-490, 1980


11) Jaques G, Rotsch M, Wegmann C, et al.  Production of immunoreactive insulin-like growth factor 1 and response to exogenous IGF-1 in small cell lung cancer cell lines.  Exp Cell Res 176:336-343, 1988


12) Nakanishi Y, Mulshine JL, Kasprzyk PG, et al.  Insulin-like growth factor-1 can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.  J Clin Invest 82:354-359, 1988


13) Lee PDK, Rosenfeld RG, Hintz RL, Smith SD.  Characterization of insulin, insulin-like growth factors I and II, and growth hormone receptors on human leukemic lymphoblasts.  J Clin Endocr Metab 62:28-35, 1986


14) Colman PG, Harrison LC.  Structure of insulin/insulin-like growth factor-1 receptors on the insulinoma cell, RIN-m5F.  Biochem Biophys Res Commun 124:657-662, 1984


15) Zapf J, Froesch ER.  Insulin-like growth factors/somatomedins:  structure, secretion, biological actions and physiological role.  Hormone Res 24:121-130, 1986


16) Papa V, Constance CR, Brunetti A, et al.  Progestins increase insulin receptor content and insulin stimulation of growth in human breast carcinomas.  Cancer Res 50:7857-7862, 1990


17) Stewart AJ, Johnson MD, May REB, Westley RB.  Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells.  J Biol Chem 265:21172-21178, 1990


18) Eppenberger U.  New aspects in the molecular growth regulation of mammary tumors.  In:  Eppenberger U, Goldhirsch A, eds.  Recent Results in Cancer Research, Vol. 113:  Endocrine Therapy and Growth Regulation of Breast Cancer.  Berlin-Heidelberg, 1989, 1-3


19) DeLeon DD, Bakker B, WIlson RL, et al.  Demonstration of insulin-like growth factor (IGF-I and IGF-II) receptors and binding protein in human breast cancer cell lines.  Biochem Biophys Res Commun 152:398-405, 1988


20) Karey KP, Sirbasku DA.  Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17B-estradiol.  Cancer Res 48:4083-4092, 1988


21) King GL, Kahn CR, Rechler MM, Nissley SP.  Direct demonstration for separate receptors for growth and metabolic activities of insulin and multiplication-stimulating activity (an insulin-like growth factor) using antibodies to the insulin receptor.  J Clin Invest 66:130-140, 1980


22) Jacobs S, Cook S, Svoboda M, Van Wyk JJ.  Interaction of the monoclonal antibodies alpha-IR-1 and alpha-IR3 with insulin and somatomedin-C receptors.  Endocrinol 118:223-226, 1986


23) Goustin AS, Leof EB, Shipley GD, Moses HL.  Growth factors and cancer.  Cancer Res 46:1015-1029, 1986


24) Unterburger P, Sinop A, Noder w, et al.  Diabetes  mellitus  and  breast  cancer:  a retrospective follow-up study.  Onkologie 13:17-20, 1990


25) Yee D, Palk S, Lebovic GS, et al. Analysis of insulin-like growth-factor I gene expression: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509-517, 1990


26) Hilf R.  Primary and permissive actions of insulin in breast cancer.  In:  Leung BS, ed.  Hormonal regulation of mammary tumors.  Montreal, Eden Press, 1982, Vol. 2, 123-137


27) Alabaster O, Vonderhaar BK, Shafie SM.  Metabolic modification by insulin enhances methotrexate cytotoxicity in MCF-7 human breast cancer cells.  Eur J Cancer Clin Oncol 17:1223-1228, 1981


28) Oster JB, Creasey WA.  Enhancement of cellular uptake of ellipticine by insulin preincubation.  Eur J Cancer Clin Oncol 17:1097-1103, 1981


29) Schilsky RL, Bailey BD, Chabner BA.  Characteristics of membrane transport of methotrexate by cultured human breast cancer cells.  Biochem Pharmacol 30:1537-1542, 1981


30) Shinitzky M, Henkart P.  Fluidity of cell membranes – current concepts and trends.  Int Rev Cytol 60:121-147, 1971


31) Jeffcoat R.  The biosynthesis of unsaturated fatty acids and its control in mammalian liver.  Essays Biochem 15:1-36, 1979


32) Gasparro FP, Knobler RM, Yemul SS, Bisaccia E, Edelson RL.  Receptor mediated photo-cytotoxicity:  synthesis of a photoactivatable psoralen derivative conjugated to insulin.  Biochem Biophys Res Comm 141:502-209, 1986


33) Poznansky MJ, Singh R, Singh B.  Insulin:  carrier potential for enzyme and drug therapy.  Science 223:1304-1306, 1984


34) Ayre SG.  New approaches to the delivery of drugs to the brain.  Med Hypotheses 29:283-291, 1989


35) Gross GE, Boldt DH, Osborne CK.  Perturbation by insulin of human breast cancer cell kinetics.  Cancer Res 44:3570-3575, 1984


36) Paridaens R, Klijn JGM, Julien JP, et al.  Chemotherapy with estrogenic recruitment in breast cancer:  experimental background and clinical studies conducted by the EORTC breast cancer cooperative group.  Eur J Cancer Clin Oncol 22:728, 1986


37) Van der Burg B, de Laat SW, van Zoelen EJJ.  Mitogenic stimulation of human breast cancer cells in a growth-factor defined medium:  synergistic action of insulin and estrogens.  In:  Brescani F, King RGB, Lippman ME, Raynaud JP, eds.  Progress in Cancer Research and Therapy, vol. 35:  Hormones and Cancer 3.  New York, Raven Press, Ltd.  1988, 231-233.


38) Goldfine ID, Purello F, Vigneri R, and Clawson GA.  Direct regulation of nuclear functions by insulin:  relationship to mRNA metabolism.  In:  Czech MP, ed. Molecular Basic of Insulin Action.  New York, Plenum Press, 1985, 329-345.


39)Blood Brain Barrier Passage of Azidothyumidine in Rats: Effects of Insulin

Steven G. Ayre (1), Brian Skaletski (2) and Aron D. Mosnaim( 2). 

Research Communications in Chemical Pathology and Pharmacology JANUARY 1989 VOL.63, NO. 1. Departments of Family Medicine and Pharmacology and Molecular Biology , University of Health Sciences/The Chicago Medical School, North Chicago, IL 60064.


40)New Approaches to Delivery of Drugs to the Brain. S.G. Ayre. Medical Hypotheses 29:283-291, 1989


41)Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer. S.G. Ayre, M.D., D. P. Garcia Bellon, M.D., D. P. Garcia, Jr., M.D. Medical hypotheses 55.4 (2000): 330-334.


42)Low dose chemotherapy in combination with insulin for the treatment of metastatic tumors: C. Damyanov, M. Radoslavova, V. Gavrilov, D. Stoeva. Medical Center of Integrative Medicine, Sofia, Bulgaria. Journal of BUON 14: 711-15, 2009.


43)Insulin Potentiation Therapy in the treatment of malignant neoplastic diseases: a three year study. Damyanov C, Gherasimova DM, Avramov LA, Masley IK (2012). J Cancer Sci Ther 4: 088-091. doi:10.4172/1948-5956.1000117


44)Low-Dose Chemotherapy with insulin (Insulin Potentiation Therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer. Damyanov, Christo, et al. ISRN urology 2012 (2012).


45)Metabolic Modification by Insulin Enhances Methotrexate Cytotoxicity in MCF-7 Human Breast Cells. Alabaster, O. Vonderhaar, B. and Shafie, S. Eur J Cancer Clin Oncol. Vol 17, No. 11, pp 1223-1228. 1961. 


46)Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Lundholm K, Körner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, Bosaeus I. Clin Cancer Res. 2007 May 1;13(9):2699 706.


47)Long-Term Effect of Diabetes and Its Treatment on Cognitive Function. Jacobson, Alan, et.al. N Engl J Med 2007; 356:1842-52.


48)Preclinical safety and antitumor efficacy of insulin combined with irradiation. Bénédicte F. Jordan, Nelson Beghein, Nathalie Crokart, Christine Baudelet, Vincent Gregoire, Bernard Gallez. Radiotherapy and Oncology 81 (2006) 112–117.


49)Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients. Lasalvio-Prisco, Eduardo, et.al. Cancer Chemother Pharmacol (2004) 53: 220–224.


50)The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells. Zhonghua Yi Xue Za Zhi. 2003 Feb 10;83(3):195-7. 


51)Pretreatment with insulin enhances anticancer functions of 5-fluorouracil in human esophageal and colonic cancer cells. Zou K, Ju JH, Xie H. Acta Pharmacol Sin. 2007 May; 28(5):721-30. 


52)A pilot study of Auron Misheil Therapy (AMT) in patients with advanced cervical cancer: tumor response and its correlation with clinical benefit response, and preliminary quality of life data.” Scheele, Jürgen, et al. Oncology reports 22.4 (2009): 877-883.


53)Insulin in endometrial carcinoma chemotherapy: A beneficial addition and not a problem. Sha, Huilan, et al. Journal of Huazhong University of Science and Technology [Medical Sciences] 30 (2010): 631-637.


54) Insulin for Everything. TIME magazine April 10, 1944


55)Long-Term Outcomes of the Treatment of Unresectable (Stage III - IV)Ductal Pancreatic Adenocarcinoma Using Metabolically Supported Chemotherapy (MSCT): A Retrospective Study

Mehmet Salih Iyikesici1, Ayshe Slocum2*, Engin Turkmen3, Ovunc Akdemir4, Abdul Kadir Slocum5, Turgut Ipek6, Erhun Eyuboglu6, Ferhan Bulent Berkarda7


56)Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer. Mehmet Salih İyikesici, Abdul Kadir Slocum, Ayshe Slocum, Ferhan Bulent Berkarda, Miriam Kalamian, andThomas N Seyfried. Cureus. 2017 Jul; 9(7): e1445.Published online 2017 Jul 7. doi:  10.7759/cureus.1445. PMCID: PMC5589510. Monitoring Editor: Alexander Muacevic and John R Adler


57)Integrative Oncology at the Clinicist's Look. Chronology for the Creation and Development of the IPT & BMP Method for Treatment of Oncological Diseases. It is uploaded on the following link: http://www.clinicsinoncology.com/pdfs_folder/cio-v4-id1671.pdf . 



#ipt #iptld #iptldacademy #LegacyIPT #integrativemedicine #integrativecancer #naturalmedicine #alternativecancercare #cancersurvivor #cancer #cancersucks #cancerawareness #breastcancer #cancerfighter #cancerwarrior #cancersupport #cancerfree #chemotherapy #survivor #health #breastcancersurvivor #cancerdemama #cancerresearch #chemo #cancertreatment #cancercare #oncology #beatcancer #cancersurvivors #lifeaftercancer #repost #fightcancer

Comments

Popular posts from this blog

Interesting Historical Facts about the Inventor of IPT

Did you know ...? Donato Pérez García, Senior 1930’s Mexico * The inventor of Insulin Potentiation Therapy was a skillful surgeon in obstetrics, gynecology and urology? * He first injected himself with insulin in 1930, as an experiment to cure him from a lifelong gastrointestinal illness that almost killed him. * In 1930, he cured his first patient from syphilis using this methodology. * His work at the San Diego Naval Hospital earned him an article on the April 10th 1944 edition of TIME Magazine. * In 1946 he successfully treated, for the very first time, a cancer patient, achieving full remission.  HISTORICAL NOTE:  Back in those days, oncology was an inexistent specialty in medicine. The first research done on nitrogen mustard for the treatment of leukemia was done in the USA by the year 1946. Dr. Sidney Farber, from the School of Medicine in Harvard applied  methotrexate  and folic acid on a patient with Leukemia and achieved

Directory of Qualified IPT©-IPTLD® Practitioners

List of Officially Certified IPT©-IPTLD® Practitioners Welcome to the Official Directory of Qualified IPT/IPTLD Practitioners, trained and endorsed by Donato Perez Garcia, MD, Director, IPT Professor and proud owner of the Protocol “Insulin Potentiation Therapy”. Here you find the full name, geographic location, email/website of the approved health practitioners, certified to perform IPT/IPTLD on patients, worldwide. CLICK: https://donatoperezgarcia.com/ipt-education

TESTIMONY OF PATIENT JOSEPH G.

It was in 1975 that my grandmother Sofia G. had quite a large stomach tumor and the only option they offered was surgery. They’ve heard of Dr. Donato working in Mexico City and a treatment that, without surgery, could reduce or eradicate the tumor. Back in those days, Dr. Donato Pérez García Bellón (Donato 2nd generation) was beginning with his IPT.  My grandparents moved to Mexico City, rented an apartment so they didn't’ haven't to travel so much because of my grandmother’s discomfort and just have treatments for a couple of months, they were originally from Monterrey, and at the end of treatments they made tests and the tumor had practically vanished, she didn’t have anything anymore.  And well, from that point on my grandmother never had stomach problems nor recidivism of any kind, nothing. The treatment as I recall lasted about 2 or 3 months. She lived well many years and died from old age over 30 years ago.  After that, my aunt had problems with breast cancer and in